x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DCL-001069
| Product Information | |
|---|---|
| Parental | HeLa |
| Organism | Human |
| Tissue | Cervix |
| Target Name | RIPK2 |
| Cell Type | Epithelial cells |
| Gender | Female |
| Product Description | Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1. |
| UniProt No. | O43353 |
| Gene ID | 8767 |
| Gene Description | Activates pro-caspase-1 and pro-caspase-8. Potentiates CASP8-mediated apoptosis. Activates NF-kappa-B. |
| Format | Frozen |
| Growth Properties | Adherent |
| Shipping & Storage | |
|---|---|
| Shipping | Cryopreserved on dry ice. |
| Storage Instructions | Store in liquid nitrogen. |
| Storage Buffer/Media | 8.7% Dimethylsulfoxide, 2% Cellulose, methyl ether |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
